The Prognostic Value of Echocardiography and ECG In Patients with Liver Cirrhosis: A Single-Center Prospective Cohort Study in Myanmar
Main Article Content
Abstract
Background
Cirrhotic cardiomyopathy remains under-recognized in Southeast Asia, where chronic viral hepatitis and alcohol-related liver disease frequently coexist. The prognostic relevance of the updated 2020 Cirrhotic Cardiomyopathy Consortium (CCC) criteria, particularly the use of global longitudinal strain (GLS), has not been adequately studied in this region.
Objectives
We aimed to characterize cardiac dysfunction in Myanmar patients with cirrhosis, compare the diagnostic performance of the 2005 and 2020 CCM criteria, and determine cardiac predictors of 1-year mortality.
Methods
In this prospective cohort study, 200 consecutive cirrhotic patients underwent comprehensive echocardiography with speckle-tracking analysis and standard electrocardiography. The primary endpoint was all-cause mortality at 12 months. Multivariable Cox regression was used to identify independent predictors of death.
Results
The mean age was 54±11 years. Alcohol-associated liver disease (35%), hepatitis C (30%), and hepatitis B (25%) were the predominant etiologies. Although left ventricular ejection fraction was preserved, GLS was frequently impaired (mean −16.2±3.4%). The 2020 CCC criteria identified cirrhotic cardiomyopathy in 28% of patients compared with 54% by the 2005 criteria. Thirty patients (15%) died during follow-up. GLS <16% (HR 2.10, p<0.001) and QTc prolongation >440 ms (HR 1.75, p=0.018) were independently associated with mortality after adjustment for MELD score.
Conclusions
Subclinical myocardial dysfunction is common among Myanmar patients with cirrhosis. The 2020 CCC criteria demonstrate improved prognostic discrimination. Both impaired GLS and QTc prolongation independently predict mortality and should be incorporated into routine risk stratification.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Myanmar National Hepatitis Elimination Profiles (N-HEP). (2025). https://www.globalhep.org/data-profiles/countries/myanmar.
II. Cesari M, Frigo AC, Piano S, Angeli P: Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. Clin Exp Hepatol. 2021, 7:270-7. PMID: 34712828. doi: 10.5114/ceh.2021.108708.
III. Izzy MA-O, VanWagner LA-O, Lin G, Altieri M, Findlay JY, Oh JK.: Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020, 71:334-345. PMID: 31342529.
doi: 10.1002/hep.31463.
IV. Møller S, Henriksen JH.: Cirrhotic cardiomyopathy. Journal of Hepatology. 2010, 53:179 - 190. PMID: 20462649.
doi: 10.1016/j.jhep.2010.02.023.
V. Oo SM, Myo PM, Thu AK, Zaw H, Oo TN, Zaw M: Echocardiographic Risk Stratification in a General Oncology Population in Myanmar: A Prospective Observational Study. International Journal Of Medical Science And Clinical Research Studies. 2025, 05:1665-71.
doi.org/10.47191/ijmscrs/v5-i10-04
VI. Myo PM, Zaw H, Thu AK, Oo SM: The Structural and Functional Echocardiographic Changes in Haemodialysis Patients with Chronic Kidney Disease: A Cross-Sectional Study. International Journal Of Medical Science And Clinical Research Studies. 2025, 5:
doi.org/10.47191/ijmscrs/v5-i09-03
VII. Kim SM, George B, Alcivar-Franco D, Campbell CL, Charnigo R, Delisle B.: QT prolongation is associated with increased mortality in end stage liver disease. World J Cardiol. 2017, 9:347-354. PMID: 28515853. doi: 10.4330/wjc. v9. i4.347.
VIII. Oo SM, Myo PM, Thu AK, Zaw H, Oo TN, Zaw M: The Arrhythmias in End-Stage Renal Disease on Maintenance Haemodialysis: A Cross-Sectional Study. International Journal of Medical Science and Clinical Research Studies. 2025, 5:1700-7.
doi.org/10.47191/ijmscrs/v5-i10-09
IX. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T.: Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. 2016, 17: PMID: 27422899.
doi: 10.1093/ehjci/jew082.
X. Thomas JD, Edvardsen T, Abraham T, Appadurai V, Badano L, Banchs J.: Clinical Applications of Strain Echocardiography: A Clinical Consensus Statement from the American Society of Echocardiography Developed in Collaboration with the European Association of Cardiovascular Imaging of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2025, 38:985-1020. PMID: 40864001. doi: 10.1016/j.echo.2025.07.007.
XI. Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V.: Which QT Correction Formulae to Use for QT Monitoring? J Am Heart Assoc. 2016, 5: PMID: 27317349.
doi: 10.1161/JAHA.117.004252.
doi: 10.1161/JAHA.116.003264.
XII. Ridjab DA-O, Ivan I, Budiman F, Tenggara R: Evaluation of subclinical ventricular systolic dysfunction assessed using global longitudinal strain in liver cirrhosis: A systematic review, meta-analysis, and meta-regression. PLOS ONE. 2022, 17: PMID: 35671306.
doi: 10.1371/journal.pone.0269691.
XIII. Liu HA, Ryu DA, Hwang SA, Lee SA: Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities. Int J Mol Sci. 2024, 25:5849. PMID: 38892040.
doi: 10.3390/ijms25115849.
XIV. Gao B: Interaction of alcohol and hepatitis viral proteins: implication in synergistic effect of alcohol drinking and viral hepatitis on liver injury. Alcohol. 2002, 27(1):69-72: PMID: 12062640.
doi: 10.1016/s0741-8329(02)00201-x.
XV. Razpotnik M, Bota S, Wimmer P, Hackl M, Lesnik G, Alber H.: The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. Liver Int. 2021, 41: 1058-1069. PMID: 33342074. doi: 10.1111/liv.14769.
XVI. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH: Normal Ranges of Left Ventricular Strain: A Meta-Analysis. Journal of the American Society of Echocardiography. 2013, 26:185-91. PMID: 23218891. doi: 10.1016/j.echo.2012.10.008.
XVII. Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P: Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol. 2021, 18:117-135. PMID: 32999450. doi:10.1038/s41569-020-0433-5.
XVIII. Liu H, Naser JA, Lin G, Lee SS: Cardiomyopathy in cirrhosis: From pathophysiology to clinical care. JHEP Rep. 2024, 6: PMID: 38089549.
doi: 10.1016/j.jhepr.2023.100911.
XIX. Xu HQ, Wang CG, Zhou Q, Gao YH: Effects of alcohol consumption on viral hepatitis B and C. World J Clin Cases. 2021, 9:10052-63. PMID: 34904075. doi: 10.12998/wjcc. v9. i33.10052.
XX. Bernardi M, Calandra S, Colantoni A, Trevisani F: Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998, 27: PMID: 9425913.
doi: 10.1002/hep.510270106.
XXI. Biering-Sørensen T, Biering-Sørensen SR, Olsen FJ, Sengeløv M: Global Longitudinal Strain by Echocardiography Predicts Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population. Circulation:
Cardiovascular Imaging. 2017, 10:005521. doi.org/10.1161/CIRCIMAGING.116.005521.
XXII. Ohno M, Cheng CP, Little WC: Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation. 1994, 89:2241-50. PMID: 8181149. doi: 10.1161/01.cir.89.5.2241.
XXIII. Gibbs C, Thalamus J, Heldal K, Holla ØL, Haugaa KH, Hysing J: Predictors of mortality in high-risk patients with QT prolongation in a community hospital. EP Europace. 2018, 20:99-107. PMID: 29036623. doi: 10.1093/europace/eux286.